Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose
Raphael Allgaier,
Arne Kandulski,
Karsten Gülow,
Lars Maier,
Martina Müller,
Hauke Christian Tews
Affiliations
Raphael Allgaier
Department of Internal Medicine II, Cardiology, University Medical Center Regensburg
Arne Kandulski
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Medical Center Regensburg
Karsten Gülow
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Medical Center Regensburg
Lars Maier
Department of Internal Medicine II, Cardiology, University Medical Center Regensburg
Martina Müller
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Medical Center Regensburg
Hauke Christian Tews
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Medical Center Regensburg
Abstract Background and objective Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole. Case Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole. Conclusion This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.
